- Home
- Publications
- Publication Search
- Publication Details
Title
Novel treatment concepts in Hodgkin lymphoma
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 281, Issue 3, Pages 247-260
Publisher
Wiley
Online
2016-12-19
DOI
10.1111/joim.12582
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
- (2016) John W. Sweetenham et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
- (2016) P Tsirigotis et al. BONE MARROW TRANSPLANTATION
- What to Do With Success? The Optimist’s Creed in Relapsed Hodgkin Lymphoma
- (2016) Amir K. Issa et al. Clinical Lymphoma Myeloma & Leukemia
- Recent treatment advances in Hodgkin lymphoma: a concise review
- (2016) S. Arulogun et al. INTERNAL MEDICINE JOURNAL
- Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma
- (2016) Frederika A. van Nimwegen et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Current and future immunotherapeutic approaches in Hodgkin lymphoma
- (2016) Paul J. Bröckelmann et al. LEUKEMIA & LYMPHOMA
- Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
- (2016) Jose Caetano Villasboas et al. Oncotarget
- Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics
- (2015) Ingrid Glimelius et al. AMERICAN JOURNAL OF HEMATOLOGY
- The new therapeutical scenario of Hodgkin lymphoma
- (2015) A. Stathis et al. ANNALS OF ONCOLOGY
- Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
- (2015) Robert Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
- (2015) Andres Forero-Torres et al. BLOOD
- Biologic Agents in the Management of Hodgkin Lymphoma
- (2015) Armin Rashidi et al. Journal of the National Comprehensive Cancer Network
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
- (2015) Michael Schaapveld et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study
- (2015) I. Glimelius et al. Journal of Cancer Survivorship
- A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin’s lymphoma
- (2015) Vivek Subbiah et al. Oncotarget
- Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
- (2014) M. D. Gandhi et al. BLOOD
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
- (2014) A. K. Gopal et al. BLOOD
- Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project
- (2014) Kenneth R. Carson et al. CANCER
- An update on emerging drugs for Hodgkin lymphoma
- (2014) Bastian von Tresckow et al. EXPERT OPINION ON EMERGING DRUGS
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
- (2013) Y. Oki et al. CLINICAL CANCER RESEARCH
- Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
- (2013) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
- (2013) Yuxuan Liu et al. SEMINARS IN CANCER BIOLOGY
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
- (2011) B. Glimelius et al. ANNALS OF ONCOLOGY
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
- (2011) T. A. Fehniger et al. BLOOD
- Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin’s Lymphoma - a population-based study
- (2011) Ingrid Glimelius et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
- (2009) Boris Böll et al. BRITISH JOURNAL OF HAEMATOLOGY
- Late complications after treatment for Hodgkin lymphoma
- (2008) Andrea K. Ng Current Hematologic Malignancy Reports
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started